期刊文献+

常染色体显性遗传多囊肾病中JAK2-STAT3通路对补体因子B表达的调控作用 被引量:3

JAK2-STAT3 pathway regulates the expression of complement factor B in autosomal dominant polycysfic kidney disease
原文传递
导出
摘要 目的探讨常染色体显性遗传多囊肾病(ADPKD)中JAK2.STAT3通路对补体因子B(CFB)表达的调控作用。方法收集ADPKD患者肾脏切除术后的肾组织标本,以肾癌根治术患者肾脏切除标本的正常肾脏组织为对照;收集雄性Han:SPRD(Cv/+)大鼠(ADPKD模型)和野生型Han2SPRD(+/+)大鼠4周、8周、16周时的肾组织标本;原代培养16周Han:SPRD(Cy/+)大鼠肾小管上皮细胞,分别给予JAK2抑制剂WPl066及STAT3抑制剂乙胺嘧啶作用24h,Western印迹法分别检测Cy/+大鼠、野生型大鼠、ADPKD患者及对照肾组织及各组。肾小管上皮细胞中p-JAK2、JAK2、p-STAT3、STAT3、CFB蛋白的表达。结果与对照组相比,ADPKD患者肾组织中p-JAK2、p-STAT3、STAT3、CFB蛋白表达量增加,且差异有统计学意义(均P〈0.05)。与野生型大鼠相比,Cy/+大鼠肾组织中p-JAK2、JAK2、p-STAT3、STAT3、CFB蛋白表达量增加且差异有统计学意义(均P〈0.01)。细胞实验发现,WP1066抑制Cy/+大鼠肾小管上皮细胞p-JAK2、p-STAT3、CFB蛋白的表达(均P〈0.05),且抑制程度与WP1066剂量相关;乙胺嘧啶抑制Cy+大鼠肾小管上皮细胞p-STAT3、CFB蛋白的表达(均P〈0.05)。结论ADPKD中JAK2-STAT3通路的异常激活可以促进CFB的表达,并且CFB的蛋白水平与ADPKD的病程相关,其可能参与了ADPKD囊泡的发生和发展。 Objective To investigate the role of JAK2-STAT3 pathway in the expression of complement factor B (CFB) in autosomal dominant polycystie kidney disease (ADPKD). Methods Renal tissue samples of patients with ADPKD after nephrectomy were collected. Normal renal tissue samples as control were taken from patients after radical nephrectomy. Renal tissue samples of Han: SPRD Cy/+ rats (ADPKD model) and wild- type Hart: SPRD +/+ rats were also collected at 4, 8, 16 week. Han:SPRD Cy/+ rat renal tubular epithelial cells (16 w) were primarily cultured in vitro, then stimulated with the JAK2 inhibitor (WP1066) and STAT3 inhibitor (pyrimethamine) for 24 h respectively. Western blotting was used to detect the expression of p-JAK2, JAK2, p-STAT3, STAT3, CFB protein. Results Compared with control group, the protein expressions of p-JAK2, p-STAT3, STAT3, CFB significantly increased in the renal tissue of ADPKD patients (all P 〈 0.05). The protein expressions of p- JAK2, JAK2, p- STAT3, STAT3 and CFB also significantly increased in the renal tissue of Cy/+ rats compared with wild-type rats (all P 〈 0.01). When the Cy/+ renal tubular epithelialcells were treated with WP1066, the expressions of p-JAK2, p-STAT3, CFB were suppressed (P 〈 0.05) and the degree of inhibition was correlated with the WP1066 dose. Pyrimethamine inhibited the protein expressions of p- STAT3 and CFB in the tubular epithelial cells of Cy/+ rats (all P 〈 0.05) and the degree of inhibition was correlated with the pyrimethamine dose. Conclusions The JAK2-STAT3 pathway is abnormally activated in ADPKD and increases the protein expression of CFB. CFB protein level is correlated with the progress of ADPKD, suggesting that it may take part in the growth and development of ADPKD vesicles.
出处 《中华肾脏病杂志》 CAS CSCD 北大核心 2014年第4期304-309,共6页 Chinese Journal of Nephrology
基金 国家自然科学基金(30900692)
关键词 多囊肾 常染色体显性 补体因子B JANUS激酶2 STAT3转录因子 Polycystic kidney, autosomal dominant Complement factor B Janus kinase 2 STAT3 transcription factor
  • 相关文献

参考文献19

  • 1Wuthrieh RP, Mei C. Aquaretie treatmen| in polycystie kidney disease[J]. N Engl J Med, 2012, 367: 2440-2442.
  • 2Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease[J]. Lancet, 2007, 369: 1287-1301.
  • 3Torres VE, Harris PC. Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities[J]. J Intern Med, 2007, 261: 17-31.
  • 4Xue C, Dai B, Mei C. lxmg-term treatment with mammalian target of rapamycin inhibitor does not benefit patients with autosomal dominant polycystic kidney disease: a meta-analysis IJ]. Nephron Clin Pract, 2013, 124: 10-16.
  • 5Bhunia AK, Piontek K, Boletta A, et al. PKD1 induces p21 (wafl) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2 IJl. Cell, 2002, 109: 157-168.
  • 6Mitzel DN, Jaramillo R J, Stout- Delgado H, et al. Human metapneumovirus inhibits the IL- 6- induced JAK/STAT3 signalling cascade in airway epithelium[J]. J Gen Virol, 2014, 95: 26-37.
  • 7Lesher AM, Song WC. Review: complement and its regulatory proteins in kidney diseases[J]. Nephrology (Carlton), 2010, 15: 663 -675.
  • 8Burtey S J, Riera M, Font6s M. Overexpression of complement- component genes in Ham SPRD rats a model of polycystic kidney disease[J]. Kidney lnt, 2008, 73: 1324-1325: author reply 1325.
  • 9l,ai X, Bacalla,) RL, Blazer-Yost BL, et al. Characterization of the renal cyst fluid pmteome in autosomal dominant polycystic kidney disease(ADPKD) patients[J]. Proteomics Clin Appl, 2008, 2: 1140-1152.
  • 10Talbot JJ, Shillingford JM, Vasanth S, et al. Polycystin- 1 regulates STAT ac, tivity by a dual mechanism[J]. Prnc Natl Acad Sci U S A, 2011, 108: 7985-7990.

同被引文献41

  • 1史永红,段惠军,何宁,王丽晖,刘青娟,高峰.氯沙坦对糖尿病大鼠肾小球信号蛋白JAK2和STAT3表达的影响[J].中国危重病急救医学,2005,17(11):662-666. 被引量:12
  • 2Gabow PA, Johnson AM, Kaehny WD, et al. Factors affecting the progression of renal disease in autosomal- dominant polycystic kidney disease[J]. Kidney Int, 1992, 41(5): 1311- 1319.
  • 3Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease[J]. Lancet, 2007, 369(9569): 1287-1301.
  • 4Tortes VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years[J]. Kidney Int, 2009, 76(2): 149-168.
  • 5Barua M, Cil O, Paterson AD, et al. Family history of renal disease severity predicts the mutated gene in ADPKD[J]. J Am Soc Nephrol, 2009, 20(8): 1833-1838.
  • 6Chapman AB, Devuyst O, Eckardt KU, et al. Autosomal- dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J]. Kidney Int, 2015, 88(1): 17-27.
  • 7Su Z, Wang X, Gao X, et al. Excessive activation of the alternative complement pathway in autosomal dominant polycystic kidney disease[J]. J Intern Med, 2014, 276(5): 470- 485.
  • 8Wang X, Zhang S, Liu Y, et al. Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats[J]. Kidney Int, 2013, 84(5): 962- 968.
  • 9Torres VE, Harris PC. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease[J]. J Am Soc Nephrol, 2014, 25(1): 18-32.
  • 10Higashihara E, Torres VE, Chapman AB, et al. Tolvaptan in autosomal dominant polycystic kidney disease: three years" experience[J]. Clin J Am Soc Nephrol, 2011, 6(10): 2499-2507.

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部